Alicaforsen clinical trials
How each study uses alicaforsen is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Alicaforsen
- 6
Studies by the year they started
6 studies that test it; most in 2002 (2)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2002 | 2 |
| 2003 | 1 |
| 2015 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Ionis Pharmaceuticals, Inc. (4) · Atlantic Pharmaceuticals Ltd (2)
Related medicines
As reviewed, each with the page that says it.
- One of Immunosuppressive Agents source
Studies
Open first, then newest update. How each study uses alicaforsen is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- ISIS 2302-CS27, A 6-Week, Placebo-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis.CompletedPhase 2Ionis Pharmaceuticals, Inc.NCT00063830Written as AlicaforsenHow we know
- Alicaforsen (ISIS 2302) in Patients With Active Crohn's DiseaseCompletedPhase 3Ionis Pharmaceuticals, Inc.NCT00048113Written as AlicaforsenHow we know
- ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative ColitisCompletedPhase 2Ionis Pharmaceuticals, Inc.NCT00063414Written as AlicaforsenHow we know
- Alicaforsen (ISIS 2302) in Patients With Active Crohn's DiseaseCompletedPhase 3Ionis Pharmaceuticals, Inc.NCT00048295Written as AlicaforsenHow we know
- Efficacy of Alicaforsen in Pouchitis Patients Who Have Failed to Respond to at Least One Course of AntibioticsCompletedPhase 3Atlantic Pharmaceuticals LtdNCT02525523Written as AlicaforsenHow we know
- Phase 1 Food Effect Study for Alicaforsen TabletsCompletedPhase 1Atlantic Pharmaceuticals LtdNCT03473626Written as AlicaforsenHow we know
Codes
What other systems call alicaforsen · ClinicalTrials.gg INT003803
- MeSH (NLM) C089753alicaforsenConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) J8435V445BALICAFORSENConfirmed FDA, NLM
- NCI Thesaurus C169771AlicaforsenOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C089753 | alicaforsen | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | J8435V445B | ALICAFORSEN | Confirmed FDA, NLM |
| NCI Thesaurus | C169771 | Alicaforsen | One source FDA |
Also registered as alicaforsen sodium (UNII 4TWN6SZB8W).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.